{"protocolSection": {"identificationModule": {"nctId": "NCT03416127", "orgStudyIdInfo": {"id": "PROPOLIS-METFORMIN-DM2"}, "organization": {"fullName": "University of Guadalajara", "class": "OTHER"}, "briefTitle": "Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus", "officialTitle": "Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment"}, "statusModule": {"statusVerifiedDate": "2022-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-01-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-12-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-01-23", "studyFirstSubmitQcDate": "2018-01-23", "studyFirstPostDateStruct": {"date": "2018-01-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-08-25", "resultsFirstSubmitQcDate": "2020-09-16", "resultsFirstPostDateStruct": {"date": "2020-10-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-11-02", "lastUpdatePostDateStruct": {"date": "2022-11-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Manuel Gonz\u00e1lez Ortiz", "investigatorTitle": "Researcher Professor", "investigatorAffiliation": "University of Guadalajara"}, "leadSponsor": {"name": "University of Guadalajara", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The aim of this study was to evaluate the effect of propolis or metformin on glycemic control in patients with type 2 diabetes mellitus without pharmacological treatment.\n\nAll patients received for 12 weeks propolis, metformin or placebo. Fasting serum glucose, 2-h serum glucose after oral glucose tolerance test, glycated hemoglobin A1c, a metabolic profile, areas under the curve of glucose and insulin, insulinogenic index, Stumvoll index, and Matsuda index were measured.", "detailedDescription": "A randomized, double-blind, placebo-controlled clinical trial of three pharmacological groups was carried out, with the participation of 36 patients with type 2 Diabetes Mellitus without pharmacological treatment.\n\nAt the beginning and end of the study, fasting serum glucose, 2-h serum glucose after oral glucose tolerance test, glycated hemoglobin A1c, and a metabolic profile were measured. Areas under the curve of glucose and insulin, total insulin secretion insulinogenic index), the first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index) were calculated.\n\nAll patients received for 12 weeks two capsules a day, one before the first bite of breakfast and another before the first bite of dinner. 12 of them took propolis (300 mg), another 12 received metformin (850 mg), and 12 more placebo in the same pharmacological presentation.\n\nThis protocol was approved by a local ethics committee and written informed consent was obtained from all volunteers.\n\nResults are presented as mean and standard deviation. Intra-group differences were evaluated using Kruskal-Wallis and Mann-Whitney U-tests, while inter-group differences were calculated with the Wilcoxon test; p\u22640.05 was considered significant."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Diabetes Mellitus type 2", "Glycemic control", "Propolis", "Metformin", "Pharmacological treatment-na\u00efve patients"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Propolis", "type": "EXPERIMENTAL", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.", "interventionNames": ["Drug: Propolis"]}, {"label": "Metformin", "type": "EXPERIMENTAL", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.", "interventionNames": ["Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.", "armGroupLabels": ["Propolis"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.", "armGroupLabels": ["Metformin"], "otherNames": ["Metformin hydrochloride"]}, {"type": "DRUG", "name": "Placebo", "description": "Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.", "armGroupLabels": ["Placebo"], "otherNames": ["Calcined magnesium"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Fasting Serum Glucose", "description": "The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12", "timeFrame": "Week 12"}, {"measure": "2 Hours After Oral Glucose Tolerance Test in Week 12", "description": "2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12", "timeFrame": "Week 12"}, {"measure": "Glycosylated Hemoglobin (A1C)", "description": "Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12", "timeFrame": "Week 12"}], "secondaryOutcomes": [{"measure": "Total Insulin Secretion", "description": "Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.\n\nThe insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.\n\nTotal insulin secretion was calculated with the insulinogenic index (\u0394AUC insulin/\u0394AUC glucose), the entered values reflect the total insulin secretion", "timeFrame": "Week 12"}, {"measure": "Insulin Sensitivity", "description": "Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.\n\nMatsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \\[10,000 / \u221aglucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\\]. The entered values reflect the insulin sensitivity", "timeFrame": "Week 12"}, {"measure": "First Phase of Insulin Secretion", "description": "The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12.\n\nHuman studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.\n\nFirst phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion", "timeFrame": "Week 12"}, {"measure": "AUC Glucose", "description": "Area under the curve (AUC) of glucose was calculated with the polygonal formula.\n\nThe area under the curve (AUC) of glucose, (0.5 \\* glucose (G) 0\u00b4 + (G 30\u00b4+G 60\u00b4 + G 90\u00b4) + 0.5 \\* G 120\u00b4) \\* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.", "timeFrame": "Week 12"}, {"measure": "AUC Insulin", "description": "Area under the curve (AUC) of insulin was calculated with the polygonal formula.\n\nThe area under the curve (AUC) of insulin, (0.5 \\* Insulin (I) 0\u00b4 + (I 30\u00b4+I 60\u00b4 + I 90\u00b4) + 0.5 \\* I 120\u00b4) \\* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.", "timeFrame": "Week 12"}, {"measure": "Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12", "timeFrame": "Week 12"}, {"measure": "Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12", "timeFrame": "Week 12"}, {"measure": "Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12.", "timeFrame": "Week 12"}, {"measure": "Waist Circumference", "description": "Waist circumference was evaluated at week 12 with a flexible tape", "timeFrame": "Week 12"}, {"measure": "Body Weight", "description": "The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12", "timeFrame": "Week 12"}, {"measure": "Body Mass Index", "description": "Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12", "timeFrame": "Week 12"}, {"measure": "Percentage of Fat Mass", "description": "Percentage of fat mass was evaluated through bioimpedance.", "timeFrame": "Week 12"}, {"measure": "Total Cholesterol", "description": "Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12", "timeFrame": "Week 12"}, {"measure": "Triglycerides", "description": "Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12", "timeFrame": "Week 12"}, {"measure": "High Density Lipoprotein Cholesterol (c-HDL)", "description": "c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12", "timeFrame": "Week 12"}, {"measure": "Low Density Lipoproteins Cholesterol (c-LDL)", "description": "c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12", "timeFrame": "Week 12"}, {"measure": "Very Low Density Lipoprotein (c-VLDL)", "description": "Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "timeFrame": "Week 12"}, {"measure": "Creatinine", "description": "Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques", "timeFrame": "Week 12"}, {"measure": "Uric Acid", "description": "Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques", "timeFrame": "Week 12"}, {"measure": "Systolic Blood Pressure", "description": "The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12.", "timeFrame": "Week 12"}, {"measure": "Diastolic Blood Pressure", "description": "The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12.", "timeFrame": "Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients both sexes\n* Age between 30 and 60 years\n* Mild to moderate physical activity\n* Stable body weight for at least 12 weeks prior to the study\n* BMI 25.0 - 34.9 kg/m2\n* Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with one of the following criteria (fasting blood glucose levels \\>126 mg/dl; or postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose \\>200 mg/dl\n* Informed consent signed\n\nExclusion Criteria:\n\n* Women with confirmed or suspected pregnancy\n* Women under lactation and/or puerperium\n* Previous treatment for glucose\n* Fasting glucose \u2265250 mg/dL\n* Known uncontrolled renal, hepatic, heart or thyroid diseased\n* Hypersensibility to ingredients of intervention\n* Known allergies to bee stings or their derived products\n* Triglycerides \u2265500 mg/dL\n* Total cholesterol \u2265240 mg/dL", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MANUEL GONZALEZ, PhD", "affiliation": "Intstituto de Terape\u00fatica Experimental y Cl\u00ednica.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Intstituto de Terape\u00fatica Experimental y Cl\u00ednica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara", "city": "Guadalajara", "state": "Jalisco", "zip": "44340", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "FG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "FG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "BG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "BG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46", "spread": "7"}, {"groupId": "BG001", "value": "51", "spread": "4"}, {"groupId": "BG002", "value": "50", "spread": "5"}, {"groupId": "BG003", "value": "49", "spread": "6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "18"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}]}]}, {"title": "Fasting serum glucose", "description": "Fasting serum glucose was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.3", "spread": "1.4"}, {"groupId": "BG001", "value": "8.0", "spread": "1.6"}, {"groupId": "BG002", "value": "7.7", "spread": "1.2"}, {"groupId": "BG003", "value": "7.7", "spread": "1.4"}]}]}]}, {"title": "2 hours after OGTT", "description": "2-h serum glucose was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.6", "spread": "2.1"}, {"groupId": "BG001", "value": "15.8", "spread": "2.8"}, {"groupId": "BG002", "value": "13.2", "spread": "1.9"}, {"groupId": "BG003", "value": "14.5", "spread": "2.5"}]}]}]}, {"title": "Glycosylated Hemoglobin (A1C)", "description": "Glycosylated Hemoglobin (A1C) was evaluated with liquid chromatography method.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.6", "spread": "0.8"}, {"groupId": "BG001", "value": "6.8", "spread": "0.9"}, {"groupId": "BG002", "value": "6.8", "spread": "0.9"}, {"groupId": "BG003", "value": "6.7", "spread": "0.8"}]}]}]}, {"title": "Total insulin secretion", "description": "The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.\n\nTotal insulin secretion was calculated with the insulinogenic index (\u0394AUC insulin/\u0394AUC glucose), the entered values reflect the total insulin secretion", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "index", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.5", "spread": "0.1"}, {"groupId": "BG001", "value": "0.4", "spread": "0.2"}, {"groupId": "BG002", "value": "0.5", "spread": "0.1"}, {"groupId": "BG003", "value": "0.5", "spread": "0.1"}]}]}]}, {"title": "Insulin sensitivity", "description": "Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \\[10,000 / \u221aglucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\\]. The entered values reflect the insulin sensitivity", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "index", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.0", "spread": "0.4"}, {"groupId": "BG001", "value": "1.1", "spread": "0.3"}, {"groupId": "BG002", "value": "0.8", "spread": "0.3"}, {"groupId": "BG003", "value": "1.0", "spread": "0.3"}]}]}]}, {"title": "First phase of insulin secretion", "description": "Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.\n\nFirst phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "index", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2092", "spread": "653"}, {"groupId": "BG001", "value": "1608", "spread": "736"}, {"groupId": "BG002", "value": "2221", "spread": "566"}, {"groupId": "BG003", "value": "1984", "spread": "686"}]}]}]}, {"title": "AUC glucose", "description": "Area under the curve (AUC) of glucose and insulin was calculated with the polygonal formula.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol*min/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "965", "spread": "137"}, {"groupId": "BG001", "value": "1039", "spread": "174"}, {"groupId": "BG002", "value": "930", "spread": "90"}, {"groupId": "BG003", "value": "978", "spread": "133.6"}]}]}]}, {"title": "AUC insulin", "description": "Area under the curve (AUC) of glucose and insulin was calculated with the polygonal formula.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol*min/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52541", "spread": "9165"}, {"groupId": "BG001", "value": "45323", "spread": "9005"}, {"groupId": "BG002", "value": "53869", "spread": "5053"}, {"groupId": "BG003", "value": "50577.6", "spread": "7741"}]}]}]}, {"title": "Glucose 30 min after oral glucose tolerance test", "description": "Glucose 30' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.4", "spread": "2.3"}, {"groupId": "BG001", "value": "13.7", "spread": "3.8"}, {"groupId": "BG002", "value": "12.0", "spread": "1.3"}, {"groupId": "BG003", "value": "12.7", "spread": "2.7"}]}]}]}, {"title": "Glucose 60 min after oral glucose tolerance test", "description": "Glucose 60' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15.2", "spread": "3.0"}, {"groupId": "BG001", "value": "17.2", "spread": "2.9"}, {"groupId": "BG002", "value": "14.7", "spread": "1.9"}, {"groupId": "BG003", "value": "15.6", "spread": "2.7"}]}]}]}, {"title": "Glucose 90 min after oral glucose tolerance test", "description": "Glucose 90' was analyzed with the glucose oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.7", "spread": "2.0"}, {"groupId": "BG001", "value": "17.5", "spread": "2.4"}, {"groupId": "BG002", "value": "14.3", "spread": "2.8"}, {"groupId": "BG003", "value": "15.5", "spread": "2.8"}]}]}]}, {"title": "Waist circumference", "description": "Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "101.2", "spread": "9.6"}, {"groupId": "BG001", "value": "103.4", "spread": "11.7"}, {"groupId": "BG002", "value": "103.2", "spread": "10.2"}, {"groupId": "BG003", "value": "102.6", "spread": "10.3"}]}]}]}, {"title": "Body weight", "description": "Body weight was evaluated through a bioimpedance digital scale and results are reported in kg with a decimal.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76.4", "spread": "11.5"}, {"groupId": "BG001", "value": "80.7", "spread": "14.4"}, {"groupId": "BG002", "value": "78.6", "spread": "13.1"}, {"groupId": "BG003", "value": "78.6", "spread": "12.8"}]}]}]}, {"title": "Body mass index", "description": "Body mass index was calculated as weight (kg) divided by height (m2).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.0", "spread": "4.4"}, {"groupId": "BG001", "value": "29.1", "spread": "3.7"}, {"groupId": "BG002", "value": "30.2", "spread": "3.13"}, {"groupId": "BG003", "value": "29.5", "spread": "3.7"}]}]}]}, {"title": "Percentage of fat mass", "description": "Percentage of fat mass was evaluated through bioimpedance.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% fat mass", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.8", "spread": "9.7"}, {"groupId": "BG001", "value": "30.7", "spread": "6.8"}, {"groupId": "BG002", "value": "33.8", "spread": "8.3"}, {"groupId": "BG003", "value": "32.4", "spread": "8.2"}]}]}]}, {"title": "Total cholesterol", "description": "Total cholesterol was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.0", "spread": "0.8"}, {"groupId": "BG001", "value": "4.7", "spread": "1.1"}, {"groupId": "BG002", "value": "4.7", "spread": "0.5"}, {"groupId": "BG003", "value": "4.8", "spread": "0.8"}]}]}]}, {"title": "Triglycerides", "description": "Triglycerides were analyzed with the triglycerides oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.2", "spread": "1.1"}, {"groupId": "BG001", "value": "1.7", "spread": "0.6"}, {"groupId": "BG002", "value": "2.0", "spread": "1.0"}, {"groupId": "BG003", "value": "2.0", "spread": "0.9"}]}]}]}, {"title": "High Density Lipoprotein cholesterol (c-HDL)", "description": "High-density lipoprotein cholesterol (c-HDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.0", "spread": "0.3"}, {"groupId": "BG001", "value": "0.9", "spread": "0.3"}, {"groupId": "BG002", "value": "0.9", "spread": "0.2"}, {"groupId": "BG003", "value": "0.9", "spread": "0.2"}]}]}]}, {"title": "Low-Density Lipoproteins-cholesterol (c-LDL)", "description": "Low-density lipoprotein-cholesterol (c-LDL) was calculated with the Friedewald formula as follows: LDL-c (mmol/L)= TC (mmol/L) - HDL-c (mmol/L) - \\[TG(mmol/L)/2.2\\]", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.0", "spread": "0.8"}, {"groupId": "BG001", "value": "3.0", "spread": "0.8"}, {"groupId": "BG002", "value": "2.9", "spread": "0.5"}, {"groupId": "BG003", "value": "3.0", "spread": "0.7"}]}]}]}, {"title": "Very low density lipoprotein (VLDL)", "description": "Very low density cholesterol (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.0", "spread": "0.5"}, {"groupId": "BG001", "value": "0.8", "spread": "0.3"}, {"groupId": "BG002", "value": "0.9", "spread": "0.5"}, {"groupId": "BG003", "value": "0.9", "spread": "0.4"}]}]}]}, {"title": "Creatinine", "description": "Creatinine was analyzed with the alkaline picrate technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.5", "spread": "31.8"}, {"groupId": "BG001", "value": "65.4", "spread": "21.2"}, {"groupId": "BG002", "value": "69.8", "spread": "27.4"}, {"groupId": "BG003", "value": "70.7", "spread": "26.5"}]}]}]}, {"title": "Uric acid", "description": "Uric acid was analyzed with the uric acid oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "356.9", "spread": "71.4"}, {"groupId": "BG001", "value": "315.2", "spread": "65.4"}, {"groupId": "BG002", "value": "309.2", "spread": "89.2"}, {"groupId": "BG003", "value": "327.1", "spread": "77.3"}]}]}]}, {"title": "Systolic blood pressure", "description": "Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "116.9", "spread": "8.7"}, {"groupId": "BG001", "value": "118.4", "spread": "10.6"}, {"groupId": "BG002", "value": "115.7", "spread": "7.2"}, {"groupId": "BG003", "value": "117.0", "spread": "8.8"}]}]}]}, {"title": "Diastolic blood pressure", "description": "Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76.5", "spread": "7.8"}, {"groupId": "BG001", "value": "76.2", "spread": "7.0"}, {"groupId": "BG002", "value": "73.4", "spread": "6.7"}, {"groupId": "BG003", "value": "75.4", "spread": "7.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Fasting Serum Glucose", "description": "The fasting glucose levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.6", "spread": "0.9"}, {"groupId": "OG001", "value": "7.3", "spread": "1.1"}, {"groupId": "OG002", "value": "8.2", "spread": "1.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.031", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "2 Hours After Oral Glucose Tolerance Test in Week 12", "description": "2-h serum glucose levels were evaluated at week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.1", "spread": "1.9"}, {"groupId": "OG001", "value": "13.7", "spread": "2.7"}, {"groupId": "OG002", "value": "13.2", "spread": "2.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.963", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Glycosylated Hemoglobin (A1C)", "description": "Glycosylated hemoglobin was evaluated at week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% of A1C", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.3", "spread": "0.9"}, {"groupId": "OG001", "value": "6.6", "spread": "0.8"}, {"groupId": "OG002", "value": "7.0", "spread": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.236", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Total Insulin Secretion", "description": "Total insulin secretion was calculated at week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.\n\nThe insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.\n\nTotal insulin secretion was calculated with the insulinogenic index (\u0394AUC insulin/\u0394AUC glucose), the entered values reflect the total insulin secretion", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "index", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.\n\nPeriod Title: Overall Study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.2"}, {"groupId": "OG001", "value": "0.3", "spread": "0.2"}, {"groupId": "OG002", "value": "0.5", "spread": "0.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.015", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Insulin Sensitivity", "description": "Insulin sensitivity was calculated at week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.\n\nMatsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \\[10,000 / \u221aglucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\\]. The entered values reflect the insulin sensitivity", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "index", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.\n\nPeriod Title: Overall Study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "0.6"}, {"groupId": "OG001", "value": "1.8", "spread": "1.0"}, {"groupId": "OG002", "value": "1.0", "spread": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.017", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "First Phase of Insulin Secretion", "description": "The first phase of insulin secretion was calculated at week 12 with Stumvoll index and the entered values reflect the frst phase of insulin secretion at week 12.\n\nHuman studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.\n\nFirst phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "index", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1346", "spread": "784"}, {"groupId": "OG001", "value": "996", "spread": "742"}, {"groupId": "OG002", "value": "1652", "spread": "863"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.162", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "AUC Glucose", "description": "Area under the curve (AUC) of glucose was calculated with the polygonal formula.\n\nThe area under the curve (AUC) of glucose, (0.5 \\* glucose (G) 0\u00b4 + (G 30\u00b4+G 60\u00b4 + G 90\u00b4) + 0.5 \\* G 120\u00b4) \\* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol*min/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "921", "spread": "126"}, {"groupId": "OG001", "value": "967", "spread": "116"}, {"groupId": "OG002", "value": "939", "spread": "126.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.686", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "AUC Insulin", "description": "Area under the curve (AUC) of insulin was calculated with the polygonal formula.\n\nThe area under the curve (AUC) of insulin, (0.5 \\* Insulin (I) 0\u00b4 + (I 30\u00b4+I 60\u00b4 + I 90\u00b4) + 0.5 \\* I 120\u00b4) \\* 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pmol*min/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44123", "spread": "13381"}, {"groupId": "OG001", "value": "27603", "spread": "15935"}, {"groupId": "OG002", "value": "51287", "spread": "7440"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.004", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Glucose 30 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 30' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 30' at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.3", "spread": "2.0"}, {"groupId": "OG001", "value": "12.5", "spread": "2.1"}, {"groupId": "OG002", "value": "12.0", "spread": "1.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.945", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Glucose 60 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 60' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 60' at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.1", "spread": "2.8"}, {"groupId": "OG001", "value": "15.9", "spread": "2.5"}, {"groupId": "OG002", "value": "14.2", "spread": "2.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.332", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Glucose 90 Min After Oral Glucose Tolerance Test at 12 Week", "description": "The glucose levels 90' were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the glucose 90' at week 12.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.2", "spread": "2.6"}, {"groupId": "OG001", "value": "16.6", "spread": "2.1"}, {"groupId": "OG002", "value": "14.9", "spread": "2.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.075", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Waist Circumference", "description": "Waist circumference was evaluated at week 12 with a flexible tape", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "100.7", "spread": "10.0"}, {"groupId": "OG001", "value": "102.2", "spread": "11.9"}, {"groupId": "OG002", "value": "101.5", "spread": "10.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.903", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Body Weight", "description": "The body weight was measured at week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.3", "spread": "11.3"}, {"groupId": "OG001", "value": "81.0", "spread": "15.2"}, {"groupId": "OG002", "value": "77.8", "spread": "13.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.697", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Body Mass Index", "description": "Body Mas Index was calculated at week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/m2", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.6", "spread": "4.3"}, {"groupId": "OG001", "value": "29.2", "spread": "3.8"}, {"groupId": "OG002", "value": "30.0", "spread": "2.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.668", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Percentage of Fat Mass", "description": "Percentage of fat mass was evaluated through bioimpedance.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% of fat mass", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.8", "spread": "10.3"}, {"groupId": "OG001", "value": "28.4", "spread": "6.8"}, {"groupId": "OG002", "value": "33.6", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.308", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Total Cholesterol", "description": "Total cholesterol levels were evaluated at week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "0.7"}, {"groupId": "OG001", "value": "4.6", "spread": "0.9"}, {"groupId": "OG002", "value": "4.7", "spread": "0.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.318", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Triglycerides", "description": "Triglycerides levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.8"}, {"groupId": "OG001", "value": "2.0", "spread": "1.0"}, {"groupId": "OG002", "value": "1.9", "spread": "0.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.880", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "High Density Lipoprotein Cholesterol (c-HDL)", "description": "c-HDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.3"}, {"groupId": "OG001", "value": "0.9", "spread": "0.2"}, {"groupId": "OG002", "value": "0.9", "spread": "0.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.376", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Low Density Lipoproteins Cholesterol (c-LDL)", "description": "c-LDL levels were evaluated at week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "0.5"}, {"groupId": "OG001", "value": "2.7", "spread": "0.5"}, {"groupId": "OG002", "value": "3.0", "spread": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.210", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Very Low Density Lipoprotein (c-VLDL)", "description": "Very low density lipoprotein (c-VLDL) was analyzed with the cholesterol oxidase/peroxidase technique by enzymatic colorimetric methods on an automatic analyzer.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "0.4"}, {"groupId": "OG001", "value": "0.9", "spread": "0.5"}, {"groupId": "OG002", "value": "0.9", "spread": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.880", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Creatinine", "description": "Creatinine levels were evaluated at week 12 with enzymatic/colorimetric techniques", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "55.7", "spread": "10.6"}, {"groupId": "OG001", "value": "74.2", "spread": "16.8"}, {"groupId": "OG002", "value": "63.6", "spread": "26.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.059", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Uric Acid", "description": "Uric acid levels were evaluated at week 12 with enzymatic/colorimetric techniques", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "339.0", "spread": "77.3"}, {"groupId": "OG001", "value": "327.1", "spread": "71.4"}, {"groupId": "OG002", "value": "333.1", "spread": "95.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.978", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure", "description": "The systolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "114.6", "spread": "7.4"}, {"groupId": "OG001", "value": "119.2", "spread": "11.4"}, {"groupId": "OG002", "value": "112.8", "spread": "6.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.122", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure", "description": "The diastolic blood pressure was evaluated at week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12.", "populationDescription": "Two of the study groups have one less patient due to withdrawal by subject, as mentioned in the participant flow, so the analysis of this outcome is calculated with those who finished the intervention", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.8", "spread": "7.4"}, {"groupId": "OG001", "value": "74.4", "spread": "7.9"}, {"groupId": "OG002", "value": "72.3", "spread": "3.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.551", "statisticalMethod": "Kruskal-Wallis"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Throughout the study, an average of 12 weeks", "eventGroups": [{"id": "EG000", "title": "Propolis", "description": "Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.\n\nPropolis: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 1, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Metformin", "description": "Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.\n\nMetformin: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 3, "otherNumAtRisk": 12}, {"id": "EG002", "title": "Placebo", "description": "Placebo capsules, two times per day before break-fast and dinner during 12 weeks.\n\nPlacebo: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 5, "otherNumAtRisk": 12}], "otherEvents": [{"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}]}, {"term": "Loose stools", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hyperphagia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "DR. MANUEL GONZALEZ ORTIZ", "organization": "INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA", "email": "uiec@prodigy.net.mx", "phone": "+52 3310585200", "phoneExt": "34212"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2017-04-06", "uploadDate": "2020-09-16T20:57", "filename": "Prot_SAP_000.pdf", "size": 205191}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2017-04-06", "uploadDate": "2020-09-16T20:57", "filename": "ICF_001.pdf", "size": 192635}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000011429", "term": "Propolis"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M14295", "name": "Propolis", "asFound": "Explanation", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}, {"id": "T364", "name": "Bee Products", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}